TWD 62.8
(7.72%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - TWD | -100.0% |
2022 | 3.94 Million TWD | -36.28% |
2021 | 6.19 Million TWD | -36.41% |
2020 | 9.73 Million TWD | 8.64% |
2019 | 8.96 Million TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 3.06 Million TWD | 0.0% |
2024 Q1 | 4.15 Million TWD | 0.0% |
2023 Q3 | 4.38 Million TWD | 91.06% |
2023 Q2 | 2.29 Million TWD | -27.92% |
2023 Q4 | - TWD | -100.0% |
2023 Q1 | 3.18 Million TWD | -19.37% |
2022 Q4 | 3.94 Million TWD | 0.0% |
2022 FY | 3.94 Million TWD | -36.28% |
2021 FY | 6.19 Million TWD | -36.41% |
2020 FY | 9.73 Million TWD | 8.64% |
2019 FY | 8.96 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Apex Biotechnology Corp. | 116.19 Million TWD | 100.0% |
Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | 100.0% |
Panion & Bf Biotech Inc. | 125.41 Million TWD | 100.0% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | 100.0% |
GenMont Biotech Incorporation | 20.11 Million TWD | 100.0% |
Abnova (Taiwan) Corporation | 2.6 Million TWD | 100.0% |
Adimmune Corporation | 1.91 Billion TWD | 100.0% |
Tanvex BioPharma, Inc. | 1.56 Billion TWD | 100.0% |
Polaris Group | 352.96 Million TWD | 100.0% |
UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | 100.0% |
PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | 100.0% |